- COVID-19
- Biosimilars
- Cataract Therapeutics
- DME
- Gene Therapy
- Workplace
- Ptosis
- Optic Relief
- Imaging
- Geographic Atrophy
- AMD
- Presbyopia
- Ocular Surface Disease
- Practice Management
- Pediatrics
- Surgery
- Therapeutics
- Optometry
- Retina
- Cataract
- Pharmacy
- IOL
- Dry Eye
- Understanding Antibiotic Resistance
- Refractive
- Cornea
- Glaucoma
- OCT
- Ocular Allergy
- Clinical Diagnosis
- Technology
Updated OCT system gains 510(k) clearance
Optovue has received FDA 510(k) clearance for an updated version of its proprietary spectral-domain optical coherence tomography system (RTVue XR FD-OCT system).
Fremont, CA-Optovue has received FDA 510(k) clearance for an updated version of its proprietary spectral-domain optical coherence tomography system (RTVue XR FD-OCT system).
The new version increases the number of A-scans per second to 70,000. It is scheduled to be available in the third quarter of this year.
“This FDA clearance affirms [the proprietary OCT system’s] position as the market leader, now with the fastest scan speed of any FDA-cleared device available,” said Jay Wei, Optovue chief executive officer. “We continue to leverage our experience in OCT product development and Fourier-domain technology to serve the needs of physicians and patients.”
For more articles in this issue of Ophthalmology Times eReport, click here.
